A more recent study investigated the long-term impact of SGLT2 inhibitors on patients with T2DM and NAFLD and demonstrated that these drugs diminished fibrosis in the liver tissue (Arai et al., 2022[6]). Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.